alexa Abstract | Drug Repositioning: A Review


Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article Open Access

Abstract

Drug repositioning (also referred to as drug repurposing) the process of finding new uses of existing drugs, has been gaining popularity in recent years. The availability of several established clinical drug libraries and rapid advances in disease biology, genomics and bioinformatics has accelerated the pace of both activity-based and in silico drug repositioning. Human diseases can be caused by complex mechanisms involving aberrations in numerous proteins and pathways. With recent advances in genomics, elucidating the molecular basis of disease on a personalized level has become an attainable goal. In many cases, relevant molecular targets will be identified for which approved drugs already exist, and the potential repositioning of these drugs to a new indication can be investigated. Repositioning is an accelerated route for drug discovery because existing drugs have established clinical and pharmacokinetic data. In the more conservative approach, termed “on-target repurposing,” the drug’s known pharmacological mechanism is applied to a new therapeutic indication, which in clinical terms might be quite far removed from the original one but is known to have the same pharmacological underpinning. About 80% of drug repurposing efforts that are currently ongoing (or have already resulted in a successful relaunch) have followed this route, which must not be confused with simple line extensions, e.g., a cancer drug obtaining additional approvals for other types of cancer.

To read the full article Peer-reviewed Article PDF image

Author(s): Deotarse P. P., Jain A. S., Baile. M. B., Kolhe N. S., Kulkarni A. A.

Recommended Journals

Share This Page

Additional Info

Loading
Loading Please wait..
 
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords